Demographic characteristics of study subjects
| PBC | Healthy controls | ||||
|---|---|---|---|---|---|
| Before UDCA (n=79) | After UDCA (n=37) | p Value† | (n=114) | p Value* | |
| Age, median years (min–max) | 52 (22–78) | 53 (22–78) | 47.5 (25–65) | 0.12 | |
| Gender, female (%) | 67 (84.8%) | 36 (97.3%) | 91 (79.8%) | 0.45 | |
| BMI, median kg/m2 (min–max) | 22.6 (17.6–29.0) | 22.5 (17.6–29.0) | 22.4 (16.2–29.4) | 0.45 | |
| ALT, U/L, median (min–max) | 66 (8–760.8) | 24 (6.1–93) | <0.0001 | ||
| AST, U/L, median (min–max) | 58 (9.1–510) | 28 (15–86) | <0.0001 | ||
| AKP, U/L, median (min–max) | 197 (46.9–1416) | 133 (49–300) | <0.0001 | ||
| GGT, U/L, median (min–max) | 188.5 (13–1560) | 44 (10–338) | <0.0001 | ||
| TB, μmol/L, median (min–max) | 14.3 (5.1–250.3) | 12.3 (4.1–48.8) | 0.33 | ||
| IgM, g/L, medain (min–max) | 2.965 (0.79–9.6) | 2.32 (0.36–6.16) | <0.0001 | ||
| IgG, g/L, medain (min–max) | 15.5 (10.3–30.1) | 15.2 (10.3–23.2) | 0.04 | ||
| AMA, ±, n (+%) | 77/2, 97.5% | ||||
| gp210, ±, n (+%) | 34/45, 43.0% | ||||
| sp100, ±, n (+%) | 8/71, 10.1% | ||||
*Wilcoxon rank-sum test was used to compare age and BMI between naïve PBC (n=79) and healthy controls (n=114); Fisher's exact test was used to compare gender distribution between PBC and controls.
†Paired Wilcoxon rank-sum test was used to compare clinical indices of PBC (n=37) before and after UDCA treatment.
AKP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ-glutaryltransferase; PBC, primary biliary cholangitis; TB, total bilirubin; UDCA, ursodeoxycholic acid.